Cerebrospinal fluid d-serine and glycine concentrations are unaltered and unaffected by olanzapine therapy in male schizophrenic patients
(2008) In European Neuropsychopharmacology 18(5). p.333-338- Abstract
N-Methyl d-aspartate (NMDA)-receptor hypofunction has been implicated in the pathophysiology of schizophrenia and d-serine and glycine add-on therapy to antipsychotics has shown beneficial effects in schizophrenic patients. Nevertheless, previous studies have not shown consistently altered d-serine concentrations in cerebrospinal fluid (CSF) of schizophrenic patients. To confirm and extend these results, CSF concentrations of both endogenous NMDA-receptor co-agonists d-serine and glycine and their common precursor l-serine were analyzed simultaneously in 17 healthy controls and 19 schizophrenic patients before and 6 weeks after daily olanzapine (10 mg) treatment. CSF d-serine, l-serine and glycine concentrations and their relative... (More)
N-Methyl d-aspartate (NMDA)-receptor hypofunction has been implicated in the pathophysiology of schizophrenia and d-serine and glycine add-on therapy to antipsychotics has shown beneficial effects in schizophrenic patients. Nevertheless, previous studies have not shown consistently altered d-serine concentrations in cerebrospinal fluid (CSF) of schizophrenic patients. To confirm and extend these results, CSF concentrations of both endogenous NMDA-receptor co-agonists d-serine and glycine and their common precursor l-serine were analyzed simultaneously in 17 healthy controls and 19 schizophrenic patients before and 6 weeks after daily olanzapine (10 mg) treatment. CSF d-serine, l-serine and glycine concentrations and their relative ratios were similar between schizophrenic patients and controls and no differences were observed before and after olanzapine therapy. Thus, the NMDA-receptor hypofunction hypothesis in schizophrenia is not explained by olanzapine therapy-dependent absolute or relative decreases in CSF d-serine and glycine concentrations in this series of male patients, thereby not providing convenient markers for the disorder.
(Less)
- author
- Fuchs, Sabine A. ; De Barse, Martina M.J. ; Scheepers, Floor E. ; Cahn, Wiepke ; Dorland, Lambertus ; de Sain-van der Velden, Monique G. ; Klomp, Leo W.J. ; Berger, Ruud ; Kahn, René S. and de Koning, Tom J. LU
- publishing date
- 2008-05-01
- type
- Contribution to journal
- publication status
- published
- keywords
- Cerebrospinal fluid, d-Serine;, Glycine;, NMDA-receptor;, Olanzapine;, Schizophrenia;
- in
- European Neuropsychopharmacology
- volume
- 18
- issue
- 5
- pages
- 333 - 338
- publisher
- Elsevier
- external identifiers
-
- scopus:40849087780
- pmid:18261886
- ISSN
- 0924-977X
- DOI
- 10.1016/j.euroneuro.2007.12.002
- language
- English
- LU publication?
- no
- id
- 26da7b83-4dd7-4e8b-915c-767617719e47
- date added to LUP
- 2020-02-28 13:55:25
- date last changed
- 2024-06-26 12:47:00
@article{26da7b83-4dd7-4e8b-915c-767617719e47,
abstract = {{<p>N-Methyl d-aspartate (NMDA)-receptor hypofunction has been implicated in the pathophysiology of schizophrenia and d-serine and glycine add-on therapy to antipsychotics has shown beneficial effects in schizophrenic patients. Nevertheless, previous studies have not shown consistently altered d-serine concentrations in cerebrospinal fluid (CSF) of schizophrenic patients. To confirm and extend these results, CSF concentrations of both endogenous NMDA-receptor co-agonists d-serine and glycine and their common precursor l-serine were analyzed simultaneously in 17 healthy controls and 19 schizophrenic patients before and 6 weeks after daily olanzapine (10 mg) treatment. CSF d-serine, l-serine and glycine concentrations and their relative ratios were similar between schizophrenic patients and controls and no differences were observed before and after olanzapine therapy. Thus, the NMDA-receptor hypofunction hypothesis in schizophrenia is not explained by olanzapine therapy-dependent absolute or relative decreases in CSF d-serine and glycine concentrations in this series of male patients, thereby not providing convenient markers for the disorder.</p>}},
author = {{Fuchs, Sabine A. and De Barse, Martina M.J. and Scheepers, Floor E. and Cahn, Wiepke and Dorland, Lambertus and de Sain-van der Velden, Monique G. and Klomp, Leo W.J. and Berger, Ruud and Kahn, René S. and de Koning, Tom J.}},
issn = {{0924-977X}},
keywords = {{Cerebrospinal fluid; d-Serine;; Glycine;; NMDA-receptor;; Olanzapine;; Schizophrenia;}},
language = {{eng}},
month = {{05}},
number = {{5}},
pages = {{333--338}},
publisher = {{Elsevier}},
series = {{European Neuropsychopharmacology}},
title = {{Cerebrospinal fluid d-serine and glycine concentrations are unaltered and unaffected by olanzapine therapy in male schizophrenic patients}},
url = {{http://dx.doi.org/10.1016/j.euroneuro.2007.12.002}},
doi = {{10.1016/j.euroneuro.2007.12.002}},
volume = {{18}},
year = {{2008}},
}